Slide 1: For personal use only
For personal use only Release authorised by the Managing Director and Chief Executive Officer Imugene Limited
Slide 2: Important notice and disclaimer
1. The information in this presentation does not constitute personal investment performance or achievements of the Company to be materially different advice. The presentation is not intended to be comprehensive or provide all from any future results, performance or achievements expressed or implied
Slide 3: FDA approved CAR T therapies and response rates
OVERALL FIRST FDA APPROVED BRAND COMPANY TARGET RESPONSE APPROVAL CANCERS RATE For personal use only 2017 CD19 B-ALL, DLBCL 53-86% 2017 CD19 DLBCL, R/R FL 72-91% 2020 CD19 R/R MCL 65*-87% 2021 CD19 DLBCL 73-87% 2021 BCMA R/R MM 72% 2022 BCMA R/R MM 98% *Overall complete remission rate https://www.hc
Slide 4: Four unique platforms maximize Imugene opportunities in cancer
FOUR UNIQUE PLATFORMS MAXIMIZE <IMUGENE OPPORTUNITIES IN CANCER Treatments that can be combined with and enhance outcomes of existing standards of care 2 Cc je) oO 12) >/ — Allogeneic | B Cell © CART Cell Therapy | Immunotherapy je) Yn pee \ oO — jos ; _ Azer-cel CHECKvacc VAXINIA HER-Vaxx PD1-Vaxx
Slide 5: Market capitalisation, cash and capital raising overview
MARKET A$591M PRO-FORMA A$196.6M 9 August 2023 30 June 20231 CAPITALISATION CASH AS OF US$389M US$143M • Imugene is undertaking a capital raising of A$60m, via a $30m Placement and $30m share purchase plan For personal use only • Funds raised will support the license of a late-stage allogeneic cell
Slide 6: Azer-cel CD19 allogeneic CAR T
For personal use only AZER-CEL CD19 ALLOGENEIC CAR T Gy) IMUGENE BIOSCIENCES % PRECISION \ \ Allogeneic | CAR T Cell Therapy | Aze r-cel
Slide 7: Imugene licenses allogeneic CAR T drug azer-cel
Imugene has licensed a near term potential registrational stage, off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. For personal use only Imugene can also use this drug to combine with its existing onCAR19 to treat solid
Slide 8: Unique opportunity to develop allogeneic CD19 CAR T drug
Unique opportunity to develop highly promising allogeneic (off the shelf) CD19 CAR T drug in blood cancers with improved safety & strong efficacy For personal use only Highly complementary to IMU’s existing CD19 OnCARlytics program Robust & compelling data package from large 84 patient Phase 1 trial
Slide 9: Licensing terms
A$11.9M upfront For personal use only A$19.4M deferred consideration (cash and/or equity upon Imugene’s discretion) A$11.9M (cash and/or equity upon start of Phase 2 registrational trial) Milestone payments industry standard rates Royalties based on industry standard rates
Slide 10: How autologous CAR T works
For personal use only 1 2 3 T Cells are taken from patients (highly dependent on patients’ The re-programmed CD 19 T When the CD19 T Cells see immune system) with blood Cells are then injected back the cancer cells with CD19 on cancers such as leukemia & into the cancer patient them, the T Cells att
Slide 11: How allogeneic off-the-shelf CAR T works
For personal use only 1 2 3 HEALTHY donors provide T Cells to As an "off the shelf" product, the make the CART product candidate. processed batches can be frozen When the CD19 T Cells see Donor T cells are processed for and shipped to multiple hospitals the cancer cells with CD19 on "universal match
Slide 12: Autologous versus allogeneic CAR T
For personal use only AUTOLOGOUS ALLOGENEIC • Limited patient access • Broad patient access • Long and complex manufacturing process • Available on demand and off-the-shelf and wait time (requires leukapheresis and immediately (no leukapheresis and no bridging bridging is often required) required) •
Slide 13: Diffuse large B-cell lymphoma overview
• Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non- For personal use only Hodgkin lymphoma (NHL) that develops from the B-cells in the lymphatic system, which are responsible for producing antibodies typically to fight infectious disease. • DLBCL develops when some of your B-cells
Slide 14: DLBCL treatment lines and post CAR T patient pool
For personal use only • High dose chemotherapy w/ stem cell transplant • R-CHOP (Combination • Auto CD19 CAR T cell • No standard of care – for Chemotherapy*) therapies: Yescarta (Gilead), auto CAR T relapse patients Kymriah (Novartis), Breyanzi (BMS) 1st line 2nd line 3rd line Pool of post CAR T ~6
Slide 15: Patients treated with azer-cel
Aze-cel For personal use only 84 Patients Treated With Azer-cel 61 23 Non-Hodgkin lymphoma B-Cell lymphoblastic leukaemia (NHL) Patients (B-ALL) Patients 58% ORR1 All Doses / All LD* Regimens 61% ORR 41% CR2 61% CR/CRi 1 ORR: Overall Response Rate 2CR: Complete Response *lymphodepletion Note: Based
Slide 16: Azer-cel results in CAR T relapse patients
Azer-cel For personal use only Across All Subjects All Doses / All LD Regimens 61 NHL Patients CAR T Relapse Pts 18 83% ORR Patients 61% CR Rate 55% DoR ≥ 6-months1 *Median duration in ≥ 6-month responders is 431 days ★ Azer-cel has the potential to provide new standard of care for this high-risk po
Slide 17: CD19 positive disease persists after relapse
Azer-cel For personal use only ~85% of patients continue to have CD19+ disease 1 In our prospective data, patients continue to have antigen positive disease 60-65% of patients currently treated with Auto CD19 CAR T will relapse (Fail)2 ★ By 2025, Global CAR T Relapse Patient Pool Is Expected To Grow
Slide 18: Azer-cel DLBCL peak sales potential
• ~30,0001 patients with DLBCL in the US with 33% likely to For personal use only be relapsed/refractory setting (1st line chemo combo) • 60%-65% will be refractory or relapsed post an autologous CD19 CART therapy (estimated 6,400 patients) • Approved auto CAR T priced at $375,000 per one-time treat
Slide 19: Autologous CD19 CAR T market growing
For personal use only Autologous CD19 CAR T Market $2.2B Annual Projected for 2023 Growing: ~60-70% of Patients Progress
Slide 20: Registrational study plan and FDA guidance
For personal use only • Potential registrational study (FDA approval) to start upon completion of the Phase 1B study H2 2024 • Population: auto CAR T failures in DLBCL patients • Positive formal and informal FDA guidance on the potential registrational study • ~35+ sites in the U.S.: Phase IB trial
Slide 21: Manufacturing facility in Durham, NC
For personal use only • Manufacturing – 32,800 (17,300 manufacturing +15,500 expansion) sq ft facility in Durham, NC Fully GMP compliant • GMP compliant / FDA inspected • Turn-key solution ready for final registrational trial drug product supply • Robust and validated process for 84 patients dosed t
Slide 22: Strategic fit with onCARlytics and solid tumours
For personal use only • Enables Imugene to progress its own combination solution in multiple solid tumour indications • Strengthen current development of onCARlytics by adding an in house off the shelf CD19 CAR T • Enables and boosts Imugene’s footprint in the blood cancer and continued solid tumour
Slide 23: Deal summary of allogeneic CAR T licences
Deal Summary For personal use only Date Deal Type (Licensor, Technology Indication Stage Financials ($USD) Licensee) Exclusive Blood and Phase 1B/2 $8m upfront + $13m Aug Precision Bio Allo CAR T cell worldwide Solid Tumour (registrationa deferred 2023 Imugene therapy license Oncology l to market) c
Slide 24: Key events and timeline
Key Events: For personal use only • Q3, 2023: FDA Process 1.2 Drug Lot Release (validating Phase 2 registrational study drug) • Q4, 2023: First Patient in for Phase 1b Expansion • Q4, 2023 – Q2, 2024: Patient recruitment status and completion of enrolment of Phase 1b • Q3, 2024 – Q4, 2024: Phase 1b
Slide 25: Imugene has licensed azer-cel
Imugene has licensed a near term potential registrational stage, off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. For personal use only Imugene can also use this drug to combine with its existing onCAR19 to treat solid
Slide 26: Placement and share purchase plan terms
• Placement to raise approximately A$30.0 million (“Placement”) Placement • Approximately 357.1m new Shares under the Company’s existing placement capacity under ASX Listing For personal use only Rules 7.1 • The offer price of A$0.084 per share (“Placement Price”) represents: Placement Pricing • A d
Slide 27: Use of funds
For personal use only USE OF FUNDS A#039;M Upfront payment 11.9 Equity or cash on successful completion of Phase 1b 11.9 Equity or cash 12 months after signing 19.4 Phase 1b Clinical trial costs 8.7 CAR T CMC/Manufacturing 8.1 Total 60.0 1 Assumes capital raising is fully subscribed and includes upfron
Slide 28: Indicative timetable
Event AEST For personal use only Trading halt Wednesday, 16 August 2023 Record Date for SPP Thursday, 17 August 2023 Placement announced & Shares resume trading on ASX Friday, 18 August 2023 Placement settlement of new Shares Thursday 24 August 2023 Placement issue of new Shares Friday, 25 August 20
Slide 29: International offer restrictions
This Deal Sheet does not constitute an offer of New Shares or New Options in any jurisdiction in which it would be unlawful. In particular, this Deal Sheet may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permi
Slide 30: Contact
Contact shareholderenquiries@imugene.com www.imugene.com 4) IMUGENE Developing Cancer Immunotherapies al use only